{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:23:11Z","timestamp":1761528191839,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.vph.2022.106955","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T23:10:16Z","timestamp":1642633816000},"page":"106955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes"],"prefix":"10.1016","volume":"143","author":[{"given":"Maria","family":"Mart\u00ednez-Urbistondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Moreno-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Mora-Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Exp\u00f3sito-Palomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Castej\u00f3n-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Daimiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Ramos-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"San-Crist\u00f3bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan A.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Alfredo","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vph.2022.106955_bb0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.vph.2022.106955_bb0010","first-page":"1","article-title":"Comorbidity and its impact on patients with COVID-19","volume":"25","author":"Sanyaolu","year":"2020","journal-title":"SN Compr. Clin. Med."},{"key":"10.1016\/j.vph.2022.106955_bb0015","doi-asserted-by":"crossref","DOI":"10.20960\/nh.03469","article-title":"Evolution of patients infected with SARS-CoV-2 according to previous metabolic status","author":"Mart\u00ednez Urbistondo","year":"2021","journal-title":"Nutr. Hosp."},{"issue":"11","key":"10.1016\/j.vph.2022.106955_bb0020","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13128","article-title":"Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships","volume":"21","author":"Popkin","year":"2020","journal-title":"Obes. Rev."},{"issue":"8","key":"10.1016\/j.vph.2022.106955_bb0025","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41440-020-0485-2","article-title":"COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study","volume":"43","author":"Huang","year":"2020","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.vph.2022.106955_bb0030","doi-asserted-by":"crossref","first-page":"2914275","DOI":"10.1155\/2020\/2914275","article-title":"Inflammatory-related clinical and metabolic outcomes in COVID-19 patients","volume":"2020","author":"Martinez-Urbistondo","year":"2020","journal-title":"Mediat. Inflamm."},{"issue":"11","key":"10.1016\/j.vph.2022.106955_bb0035","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40266-020-00808-4","article-title":"The cross-talk between age, hypertension and inflammation in COVID-19 patients: therapeutic targets","volume":"37","author":"Casucci","year":"2020","journal-title":"Drugs Aging"},{"issue":"11","key":"10.1016\/j.vph.2022.106955_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042712","article-title":"Retrospective cohort study of admission timing and mortality following COVID-19 infection in England","volume":"10","author":"Alaa","year":"2020","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.vph.2022.106955_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170811","article-title":"Validity of the Manchester triage system in emergency care: a prospective observational study","volume":"12","author":"Zachariasse","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vph.2022.106955_bb0050","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/crj.13381","article-title":"Laboratory predictors of severe coronavirus disease 2019 and lung function in followed-up","volume":"15","author":"Pan","year":"2021","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.vph.2022.106955_bb0055","article-title":"Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: a systematic review and meta-analysis","author":"Martha","year":"2021","journal-title":"Postgrad. Med. J."},{"issue":"8","key":"10.1016\/j.vph.2022.106955_bb0060","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3390\/diagnostics11081327","article-title":"The value of Interleukin-6 among several inflammatory markers as a predictor of respiratory failure in COVID-19 patients","volume":"11","author":"Fujino","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"10.1016\/j.vph.2022.106955_bb0065","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options","volume":"116","author":"Guzik","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.vph.2022.106955_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2021.106829","article-title":"Endothelial cells and SARS-CoV-2: an intimate relationship","volume":"137","author":"Barbosa","year":"2021","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.vph.2022.106955_bb0075","first-page":"1","article-title":"Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19","author":"Khan","year":"2020","journal-title":"Drugs Ther. Perspect."},{"issue":"2","key":"10.1016\/j.vph.2022.106955_bb0080","first-page":"193","article-title":"Obesity and COVID-19: the ominous duet affecting the renin-angiotensin system","volume":"46","author":"Luzi","year":"2021","journal-title":"Minerva Endocrinol. (Torino)"},{"issue":"5","key":"10.1016\/j.vph.2022.106955_bb0085","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s11739-020-02364-6","article-title":"The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies","volume":"15","author":"Albini","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.vph.2022.106955_bb0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12979-020-00194-w","article-title":"COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study","volume":"17","author":"Jurado","year":"2020","journal-title":"Immun. Ageing"},{"issue":"12","key":"10.1016\/j.vph.2022.106955_bb0095","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520979151","article-title":"Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study","volume":"48","author":"Zhong","year":"2020","journal-title":"J. Int. Med. Res."},{"issue":"7","key":"10.1016\/j.vph.2022.106955_bb0100","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41440-020-0455-8","article-title":"Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19","volume":"43","author":"Kai","year":"2020","journal-title":"Hypertens. Res."},{"issue":"25","key":"10.1016\/j.vph.2022.106955_bb0105","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2022.106955_bb0110","doi-asserted-by":"crossref","first-page":"106805","DOI":"10.1016\/j.vph.2020.106805","article-title":"RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies","volume":"135","year":"2020","journal-title":"Vasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.vph.2022.106955_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4149\/av_2021_102","article-title":"Mechanisms and potential therapeutic targets of hyperinflammatory responses in SARS-CoV-2","volume":"65","author":"Chukwuma","year":"2021","journal-title":"Acta Virol."},{"issue":"3","key":"10.1016\/j.vph.2022.106955_bb0120","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/jmv.26527","article-title":"Clinical laboratory characteristics in patients with suspected COVID-19: one single-institution experience","volume":"93","author":"Fei","year":"2021","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.vph.2022.106955_bb0125","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/jmv.26411","article-title":"Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: a meta-analysis and meta-regression","volume":"93","author":"Khinda","year":"2021","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.vph.2022.106955_bb0130","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg. Microbes Infect."},{"issue":"14","key":"10.1016\/j.vph.2022.106955_bb0135","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.3390\/jcm10143112","article-title":"Proinflammatory and hepatic features related to morbidity and fatal outcomes in COVID-19 patients","volume":"10","author":"Ramos-Lopez","year":"2021","journal-title":"J. Clin. Med."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189122000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189122000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:20:08Z","timestamp":1761528008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189122000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":27,"alternative-id":["S1537189122000040"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2022.106955","relation":{},"ISSN":["1537-1891"],"issn-type":[{"type":"print","value":"1537-1891"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2022.106955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106955"}}